Table 3.
Relationship between age and clinical trial understanding in patients who had not initiated cancer-directed therapy (n=55)
| Age; n (%) | ||||
|---|---|---|---|---|
| <65 | ≥65 | Chi-Square | P value | |
| To cure the patients in the clinical trial | 3.93 | .14 | ||
| Yes | 8 (24.2) | 4 (18.2) | ||
| No | 17 (51.5) | 7 (31.8) | ||
| I don’t know | 8 (24.2) | 11 (50.0) | ||
| To reduce as much as possible the lymphoma of patients in the trial | 7.85 | .02 | ||
| Yes | 21 (63.6) | 8 (36.4) | ||
| No | 8 (24.2) | 4 (18.2) | ||
| I don’t know | 4 (12.1) | 10 (45.5) | ||
| To keep the lymphoma of patients in the trial from getting worse | 7.86 | .02 | ||
| Yes | 20 (60.6) | 9 (40.9) | ||
| No | 9 (27.3) | 3 (13.6) | ||
| I don’t know | 4 (12.1) | 10 (45.5) | ||
| To advance research on treatments for indolent lymphoma | .69 | .71 | ||
| Yes | 28 (84.8) | 19 (86.4) | ||
| No | 1 (3.0) | 0 (0) | ||
| I don’t know | 4 (12.1) | 3 (13.6) | ||